Drug intelligence / Profile preview

STR-04

Development stage: Phase 2
Lead developer: New England Cell Therapeutics
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

STR-04 is an investigational stem cell replacement therapy initially developed by New England Cell Therapeutics. It is designed as a regenerative medicine approach, likely involving the transplantation or infusion of stem cells to replace or repair damaged tissues. The specific mechanism of action, disease targets, and further clinical details are not fully disclosed in public sources. Its highest global R&D status is not specified beyond being in development[1].

Other names: autologous bone marrow-derived mesenchymal stem cells

Beyond the preview

Go deeper on STR-04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STR-04.

Explore the full profile